Murata is seeking startups for trials of its innovative cell fractionation filter, CELLNETTA, to evaluate key challenges in various Bioresearch cases this product can resolve or surmount. CELLNETTA was created with Murata's ultra-microfabrication technology and delivers a metal alloy mesh with a high-precision aperture ratio and uniform pore sizes to achieve faster and more accurate cell size separation. Compared to cell sorters, magnetic beads, and gravity separation methods, CELLNETTA enables exceptionally fast performance as well as effectively isolates cells, keeping good cell viability and low cell stress, ensuring high cell yield, and preserving precious tissues.
Murata is committed to the development of innovative technologies that empower biotech design engineers to create revolutionary tools and devices for bioresearch and healthcare. The company’s extensive portfolio enables the development of improved patient monitoring, increased intelligence for life supporting transplants, and enhanced diagnostic imaging. The future of bioindustry and healthcare relies on technology, technology relies on Murata.
ELIGIBILITY CRITERIA :
To learn more about this trial opportunity, contact Iryna Harbar Morgan, Iryna.Harbar@murata.com
Disclaimer: MIT Startup Exchange can make introductions that ideally provide open ended discussions in order to share mutual interests and potentially create common ground that incite the parties to collaborate. MIT Startup Exchange introductions may eventually lead to mutual partnerships, but that is not in any way guaranteed by MIT, MIT Corporate Relations, MIT Industrial Liaison Program (ILP) or MIT Startup Exchange, which takes no responsibility for these outcomes and no formal part in such discussions following our introduction. MIT Startup Exchange and its activities and events are not for purposes of soliciting investment or offering securities.